<SEC-DOCUMENT>0001144204-19-013136.txt : 20190411
<SEC-HEADER>0001144204-19-013136.hdr.sgml : 20190411
<ACCEPTANCE-DATETIME>20190311060640
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001144204-19-013136
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20190311

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			20100
		BUSINESS PHONE:		972-4-988-9488

	MAIL ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			20100

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;<IMG SRC="image_001.jpg" ALT="" STYLE="height: 0.57in; width: 1.73in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">March 11, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Mary Mast</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Angela Connell</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">U.S. Securities and Exchange Commission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Division of Corporation Finance</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Mail Stop 4720</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">100 F Street, N.E.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Washington, D.C. &nbsp;20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 0.5in; padding: 0; text-indent: 0">Re:</TD>
    <TD STYLE="padding: 0; text-indent: 0"><U>Protalix BioTherapeutics, Inc.</U></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><U>Form 10-K for the Fiscal Year Ended December
    31, 2017</U></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><U>Filed March 6, 2018</U></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><U>Form 10-Q for the Quarterly Period Ended September
    30, 2018</U></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><U>Filed November 7, 2018</U></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><U>File No. 001-33357</U></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Transmitted herewith is the response of Protalix
BioTherapeutics, Inc. (the &ldquo;Company&rdquo; or &ldquo;Protalix&rdquo;) to the Staff&rsquo;s comments to our Annual Report
on Form 10-K for the year ended December&nbsp;31, 2017 (the &ldquo;Form 10-K&rdquo;) and Quarterly Report on Form 10-Q for the
quarter ended September&nbsp;30, 2018 (the &ldquo;Form 10-Q&rdquo;), which were set forth in the Staff&rsquo;s letter dated February&nbsp;13,
2019 (the &ldquo;Second Comment Letter&rdquo;) to Yossi Maimon, our Chief Financial Officer. The original comment letter was dated
December 4, 2018, and our initial response was filed on December 27, 2018. For ease of reference, we have noted the Staff&rsquo;s
comments in bold-faced type and the responses in regular type.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Notes to the Consolidated Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>d. Revenue Recognition, page 8</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
acknowledge your response to comment one. Please address the following as it relates to your determination that the performance
obligations represented a single performance obligation since the license, clinical development and manufacturing and supply obligations
were not distinct:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: left"><B>how your statement on page 2 of your response that Chiesi was not granted any other rights to,
or benefits from, the intellectual property is consistent with Section 2.1b of the agreements. The agreements appear to give Chiesi
the right to use Protalix Technology as necessary to (i) seek and obtain Regulatory Approval for the Licensed Product in the Field
in the Territory.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 8pt">2 Snunit Street,
Science Park P.O.B. 455, Carmiel 20100, Israel</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 8pt">Tel: 972-4-988-9488
| Fax: 972-4-988-9489 | Web: www.protalix.com&#9;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: left"><B>why the license and research and development services, either alone or combined, are not capable
of being distinct from the manufacturing services pursuant to ASC 606-10-25-19a. In this respect, the subcontracting and sublicensing
rights in Section 2.4 and step-in rights in Section 3.2 of the agreements appear to indicate there may be available resources outside
of the company that could provide the research and development services and supplies. Refer also to Example 56, Case B in ASC 606-10-55-371
through 55-372. In this regard, we note in Case A that an approved drug is provided in the contract with manufacturing services,
for which no other promised goods or services are included in the contract, which appears to be contrary to the company&rsquo;s
facts and circumstances. </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: left"><B>why the license and research and development services, either alone or combined, are not separately
identifiable from the supply obligation and thus do not meet the criteria in ASC 606-10-25-19b. In this regard, it appears due
to the subcontracting and sublicensing rights, the license and research and development services are not interrelated with the
manufacturing services pursuant to ASC 606-10-25-21c. Refer also to Example 56, Case B, ASC 606-10-55-372A. </B>
</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;<BR>
<U>Response</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; background-color: white">The Company
reviewed its position in light of the Staff&rsquo;s comments and will change its accounting analysis of the arrangements with Chiesi
Farmaceutici S.p.A. (&ldquo;Chiesi&rdquo;) and related revenue recognition, as detailed below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; background-color: white">After review
of the Staff&rsquo;s comments, and a subsequent reconsideration of applicable accounting guidance in ASC 606-10-25-14 through 25-21,
the Company has concluded that the <FONT STYLE="background-color: white">license and R&amp;D services are not distinct promises
and should be&nbsp;</FONT>combined as a single performance obligation. However, the Company&rsquo;s obligation to manufacture product
upon approval essentially represents an optional future purchase by Chiesi at a standalone selling price. Accordingly, in effect,
the contract contains one performance obligation for the license and R&amp;D services and an option for Chiesi to purchase manufactured
product that does not represent a material right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; background-color: white">With respect
to the license and R&amp;D services, the rationale for a combined performance obligation is as follows: Chiesi cannot benefit from
the license without the R&amp;D services. The R&amp;D services are highly specialized and depend completely on the supply of the
drug that can only be produced by the Company. Chiesi cannot supply the drug for the clinical trials by itself or with the use
of a third party (for example, a contract manufacturing organization) as the plant-based process is so complex and highly specialized
that it requires specific infrastructure and know-how that only the Company and its employees possess. The license and R&amp;D
(including the supply of product for the clinical studies) are significantly affected by each other because Protalix would not
be able to fulfill its promise by transferring each of the goods or services independently. Based on the foregoing and the factors
set forth in ASC-10-25-21, specifically 25-21(c), the Company concluded that the license is not distinct from the R&amp;D services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; background-color: white"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; background-color: white">Chiesi&rsquo;s
option to purchase commercial product manufactured by Protalix, after receipt of regulatory approval for the drug, is at standalone
selling prices (a market-based, tiered royalty arrangement common in the industry), and, therefore, does not represent a material
right. As such, the manufacture and sale of drug product is not a performance obligation as of December 31, 2018. Upon receipt
of regulatory approval, and at the request of Chiesi for Protalix to provide drug product, Protalix&rsquo;s commitment to manufacture
and sell drug product would be accounted for, in effect, as a separate contract&mdash;a modification that adds distinct goods/services
at standalone selling price&mdash;for purposes of revenue recognition under ASC 606. The performance obligation would begin after
completion of the R&amp;D services and receipt of regulatory approval for the drug.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; background-color: white">The transaction
price of the Ex-US agreement was $50 million at contract inception, which was comprised of $25 million of fixed consideration and
an estimate of $25 million of variable consideration for reimbursement of R&amp;D services. However, as those reimbursements are
subject to a cap, which is considerably less than the Company&rsquo;s expected R&amp;D costs, this consideration essentially becomes
fixed consideration. The transaction price of the US agreement was $45 million at contract inception, which was comprised of $25
million of fixed consideration and an estimate of $20 million of variable consideration for R&amp;D reimbursements, which are similarly
capped, and, in effect fixed consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; background-color: white">With respect
to the various R&amp;D milestone payments, the Company estimates variable consideration using the most likely amount method. At
contract inception and through December 31, 2018, no milestone payments were included in transaction price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; background-color: white">The method
of measuring progress for the combined performance obligation (the license and the R&amp;D services) is the cost-to-cost method,
which the Company believes best depicts the pattern of transfer to the customer. Under the cost-to-cost method, the extent of progress
towards completion is measured based on the ratio of actual costs incurred to the total estimated costs expected to be incurred
upon satisfying the identified performance obligation. Under this method, revenue will be recorded as a percentage of the estimated
transaction price based on the extent of progress towards completion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; background-color: white">The estimate
of the Company&rsquo;s measure of progress and estimate of variable consideration to be included in the transaction price will
be updated at each reporting date. For the portion of the performance obligation already satisfied, the change in transaction price
will be reflected as a change in accounting estimate. The amount related to the unsatisfied portion will be recognized as that
portion is satisfied over time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; background-color: white">Upon clarification
of this position with the Staff, subject to the approval of its Audit Committee and Board of Directors, the Company intends to
restate its 2018 quarterly financial statements, disclosing the reason for the restatement and its effect. With respect to the
2017 annual consolidated financial statements, the Company evaluated the materiality of the error from quantitative and qualitative
perspectives, and concluded that the error was immaterial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
it relates to your determination that revenue from the combined performance obligation should be recognized at a point in time
upon the supply of the drug, please address the following:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: left"><B>Your response states that you intend to recognize revenue at the point in time in which Chiesi
achieves control over batches supplied. However, you also state that you will recognize revenue as product is delivered to Chiesi
based on the quantity supplied compared to the forecasted quantity of the drug to be supplied over the term of the agreements,
which would appear to be an over time measurement. Please clarify this apparent inconsistency. Please also explain how you intend
to estimate the forecasted quantity of the drug to be supplied over the term of the agreements and how this estimate would be deemed
to be a reasonable measure of progress considering the guidance in ASC 606-10-25-36.</B>
</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: left"><B>Your response states that Protalix will &ldquo;start satisfying its performance obligation only
upon supply of the drug after issuance of regulatory marketing approvals.&rdquo; Explain how you considered the contract duration
guidance in ASC 606-10-25-3 which states that the guidance in this Topic should be applied to the duration of the contract (that
is, the contractual period) in which the parties to the contract have present enforceable rights and obligations. In this regard,
it would appear that the enforceable rights and obligations under these contracts began at their effective dates, which was October
19, 2017 for the Chiesi Ex-U.S. Agreement and July 23, 2018 for the Chiesi U.S. Agreement. Accordingly, it is unclear to us why
an over time measurement of your performance obligation would not be recognized over the entire contractual period.</B>
</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: left"><B>Explain how you considered the guidance in ASC 606-10-25-27(c) in determining whether your performance
obligation is being satisfied over time. In this regard, address the following:</B>
</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify"><B>Clarify whether your performance under the contracts
create an asset with alternative future use. In this regard, explain whether you are contractually restricted from developing
pegunigalsidase alfa (PRX-102) for your or any other entity&rsquo;s benefit as long as the Chiesi agreements are in effect.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: left"><B>Explain whether you have an enforceable right to payment for performance completed to date under
the contracts. In this regard, it would appear that you would have the full right to the non-refundable upfront payments (at a
minimum) even in the event that the drug does not receive regulatory approval and enter the commercialization phase.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><U>Response:</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">As noted in the response to Question
number 1, after reconsidering the performance obligations in the contract, the supply of product is an optional purchase. Please
refer to the response to Question number 1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">We thank you in advance for your time and
attention to this response letter. Should you wish to discuss this response letter at any time, please do not hesitate to contact
me at +972 (4) 902-8100 or YossiM@protalix.com or our counsel, Brian Hirshberg of Mayer Brown LLP at +1 (212) 506-2176 or bhirshberg@mayerbrown.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Sincerely,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">/s/ Yossi Maimon&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Yossi Maimon</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Vice President and Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Protalix BioTherapeutics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding: 0; text-indent: 0">cc:</TD>
    <TD STYLE="padding: 0; text-indent: 0">Moshe Manor</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">Protalix BioTherapeutics, Inc.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">Brian Hirshberg</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">Mayer Brown LLP</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "= =@# 2(  A$! Q$!_\0
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M:NG^+?\ R+%O_P!?:_\ H)K)^#O_ !\:M_NQ?^S4P.T_X0/PO_T!K?\ -O\
M&HW\ >%I%Q_8\(]U=A_(UT]%(9YCKWPGMWA>;1+AXI@"?(F;<C>P;J/QS7G^
MC:QJ7A+73)&KQR1-LN+=^-X'52/7WKZ.KQ_XMZ7';ZI9ZC&,-=(R28[LN,'\
MC^E,1ZKIU]!JFG6]];-NAG0.A]C7 ?&'_D$Z7_U\G_T U;^$]X\_A>>V9L_9
MKAE3/8$!OYDU4^,/_()TO_KY/_H!H R/AEX?TK6[;4FU*RBN3%(@0OG@$'/>
MN^_X0/PO_P! :W_-O\:Y3X.?\>FL?]=8_P"35Z=2 Y:7X>^%I5Q_92)[I(ZX
M_6N6USX31^4TVB7#B0<_9[@@AOHW;\:]2HH&?.FAZWJ7A'62ZJZ%&V7-J_ <
M#J"/7T/]*]^T[48-5T^"^M7WP3H'4_T^M>8_%K1XX+JSUB-<&;]S-@=2!E3^
M61^ K3^$>H/-H]]8,W%M,'3V##D?F#^=,1Z17%^./&:>&[46MIM?4IER@/(B
M7^\?Z#^E=-JNH0Z5I=U?3_ZN",N??T'XGBOGO.H>*_$?]^\OIOP7_P"L!_*D
M,ETG1M6\7ZO((V::5CNN+F8DA/=C_0?RKU_0?A[HNBHKR0K>W8ZS3KG!_P!E
M>@K8T#0[7P]I45A:+\J\NY',CGJQK6H 8JA5 48 [#BGT44 8.L^$M&UU6^U
MV2"4])XAM<'ZCK^->/\ BOP3?>&)?/W-<V#'"7"C!0]@P['WZ5[]4%S;0WEM
M+;7$:R0RJ5=&&00: /-/ 'CR2>2/1=7EWR-A;:X8\L?[C'U]#7J5?/'B[P[)
MX7UYK96;[.W[VVDSSMSZ^H/]*]@\#^(3X@\.Q33MF[A/E3^Y'1OQ'/YTQ#SX
M%\,,Q9M'M]S').6Y/YTO_"!^%_\ H#6_YM_C71T4AGS(D2'6A#M_=F[V;?;?
MC'Y5[Q_P@?A?_H#6_P";?XUX3%_R,"_]?O\ [4KZ9H YQ/ _AF.1772+<.I#
M Y/!'3O71T44 %>1?%G6O.OK;18F^2$>=,!W8_='X#)_&O4[Z[BL+">\G.(H
M4,CGV S7SO\ Z7XI\3?]/&H7'_?()_D!_*@!;C0+JV\-6>MLO[BZF>,#'0#H
M?QPWY5Z7\*-:^UZ/-I$K?O+0[XP3UC;_  .?S%=-K/AR"^\(2Z)"BA4@"P<=
M&4?*?S'ZUXKX3U=_#WBBUNI-R1AS#<+Z(>#^1Y_"F(^BJ*:&!4%>0>XIU(85
MRWQ$_P"1%U/_ '5_]#6NIKEOB)_R(NI_[J_^AK0!YW\*?^1P;_KV?^8KVVO$
MOA3_ ,C@W_7L_P#,5[;0 4444 %?.?C/_D<=9_Z^7KZ,KYS\9_\ (XZS_P!?
M+T ?0&E_\@FR_P"N"?\ H(J2YMH;NW>":-9(G&UE89!%1Z7_ ,@FR_ZX)_Z"
M*MT":35F>-^*/#$NA7/F1Y>QD/[M_P"X?[IK:\&^+3;F/3-1E_=G"P3,>G^R
M?;T_PKT&[M(+ZVDMKB-9(I!A@W>O(?$WAR?0;WN]G(3Y4GI_LGW_ )UO&2FN
M61\WBL-4P%7ZQ0^'JCU^XMX;RW>"9%DBD&UE89!%>1>*/#$VA71:/=)92']W
M)UVG^Z??^=;_ (.\78":9J+^BP3,?_'2?Y&N]O+2"]M7M[A%>)Q@@]ZA-TW9
MG95IT<SH<T?B7X/L>>^#?%WD>7IFHR?NSA896/3_ &3[>AKTD$,*\9\2^')]
M!O.\EG(?W4G_ +*??^=='X.\7[?+TO4I/189F/Y*?Z&JG!-<T3# 8Z=&?U;$
MZ-;'HU% .116)] -.<^U8'B;Q+!H-GV>ZD!\J+/7W/M3_$7B*WT&T+L0]PP/
ME19Y8^I]!7DLLM]KNJ[FWSW<[8"C^0] *TA"^K/'S',%17LJ6LW^  7VNZK_
M !SW=PW^?H!7K'AOPW;Z!:;>)+F3_6RXZ^P]JB\+^&H="L]SXDNY /,DQT_V
M1[?SKH^]$YWT0LMR_P!E^^JZS?X#J***S/9//OBW_P BQ;_]?:_^@FLGX._\
M?&K?[L7_ +-6M\6_^18M_P#K[7_T$US7PQUK3=&FU-M2O8;42K&$\QL;L;LX
M_.F(]FHKG_\ A./"_P#T'+/_ +^4QO'7AA5S_;=J?HQ-(9T=>0?%S4XY]3L-
M.C;+6Z-)(!V+8P/R'ZUK:]\5;*"%X=%B>YG(($TB[(U]\'D_I7G.EZ9J/BS7
M3$K/-<3-OGG;D(.[-_A3$>G_  EM'@\,W%RZX^T7)*^X  _GFJOQA_Y!.E_]
M?)_] -=YIFGP:5IMM86ZXB@0(OO[_4GFN#^,/_()TO\ Z^3_ .@&@"/X.?\
M'IK'_76/^35Z=7F/P<_X]-8_ZZQ_R:O3J0PHHK*UC7].T&U,^H7*1X'" Y=S
MZ*O4T <9\7;M$T6PL^/,EG\S'H%!_J15+X/0-_Q-[C^#,:?4\G_/UKB/$FO7
M7BG7#=-$PW?NK>!>2JYX'N2:]I\%:"?#_AN&VD'^DR'S9_9SV_ 8'X4Q'/\
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MQ^1K)^$NB>=?76LRI\D(\F GNQ^\?P&!^-<CXKU=_$/BBZN8MSHSB&W4=U'
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MEQ?$2D$8(3^$?ES^-,1VU%%%(9\S1?\ (P+_ -?O_M2OIFOF:+_D8%_Z_?\
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M5Z!X0\7#4D6PO6Q>(/E<\"0?XU$X+XHG7E^/ES?5\1I)?B=I11161[H4444
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MQY[#L/\ 9]?7I7MN !CL.U,C1(HU2- B*,!5& ![5)2&%%%% 'S-%_R,"_\
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MWA7QMX:3[5I>KO>HG)B5V)(_W&R&_#F@#UJBN*\&>-H_$FZSNT%OJ<0):,9
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M\"Z='#XX)"D;3^9- 'K3_P"K;Z&O*/@[_P ?VJ_]<X_YFO3K1WETN&27_6-
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ML%)*MA@<@]N?SH ]F_X2/1/^@SIW_@4G^-'_  D>B?\ 09T[_P "D_QKE/\
MA4?A[_GM??\ ?Q?_ (FC_A4?A[_GM??]_%_^)IB.=^([:<NI6&OZ-J%H]XK@
M2""96.1RK\'VQ^5>IZ7>KJ6DVEZO N(5DQZ9&:\^U#P!X,TMXTU#5KBW>091
M9)U!(]OEKT#2K&#3-*M;*W+O!#&%1G.21[T >2V^GPZE\9;BWG4-&MT\I4C(
M.U<@'\<5[17D>B_\ENN_^NL__H%>N4AGG'Q;U62VTBTTV(_\?<A:0#NJXX_$
MD?E74>$]#AT'P_;6L:CS6423OCEW(Y_P_"N*^,%JX_LF^5<HADC/L3AA_(UZ
M/I=Y%J&E6EW"V8YHE<$>XI@7:JWUE!J-E-9W,8D@F4JZGN*M44@/%/!&GOI7
MQ0.GN<FW\^/=Z@#@_EBO5?%'_(JZO_UY3?\ H!KS3PW>Q:C\8[F[A.8Y&FV,
M.A 7;G]*]+\4?\BKJ_\ UY3?^@&F(\Y^$^A0SW%UK,Z!S 1%!GG#8RS?7&/S
M->N5YK\(;^-])OM/W#S8Y_.QZJR@?S6O2J3&%>1?$FP_L'Q'I_B'3QY<LKEG
MV\9D7!S^(X->NUY;\7[Q&BTS3TYG9FEVCJ!]T?F<_E0@/1DOHVTD:A_RS, G
M_#;NKR3P+-8ZGXIOO$&MWEM'(K;XEN)53+MW )_A'%>H1Z>X\)IIO_+06(@_
M'9MKR'P'X7TOQ)<7MIJ4MQ'=0!618G"Y'(;J#T./SIB/8O\ A(]$_P"@SIW_
M (%)_C1_PD>B?]!G3O\ P*3_ !KE/^%1^'O^>U]_W\7_ .)H_P"%1^'O^>U]
M_P!_%_\ B: .6\<S6&E>*K#Q!HMY;22.V^5;>56^=>I.#_$#BO88)DGMXIU^
M[(H=?H1FO-KWP%X*TZZ2VN]5N()Y "D;SJ&()P/X?6O1[6W2TM(;:/)2)%C!
M/)( QS0,\N^'/_)0]>_W9O\ T<*]9KR3P _D?$G6H9.'<3* ?42@UZW2 *\C
M^&7_ "/6M?\ 7*3_ -&BO668*I+' '))KR/X72"7QGJTB_=>!V'T\T4 >OUY
M/??\EUA_WH__ $37K%>3WW_)=8?]Z/\ ]$T >L5Y;\9/]1HWUF_DE>I5Y;\9
M/]1HWUF_DE 'H5M,EMH45PWW([97/T"YKS'X>V/_  DGB>_\07_[UHI-R!N0
M)&SC_OD#C\*])$#W/A?[.OWY;+8/J4Q7GWP@O$A;5-,E^6?*RA3QG'RM^1Q^
M=,1ZM1112&<IKG@73-=U6/4GFN;6[0#Y[=E7<1T)R#R*U];TPZIH%[IV_#SP
M-&'/KC@G\:OR31Q8$DB+G^\V,U(.>?6@#RGP?XPC\+Q'P]X@@EM7@<[)2A(
M)S\W?&2<$9ZUZ99W]IJ, GL[F*>,_P 43AA5?5M"TO7(/*U&SBG Z,PPR_0]
M17GNL^ [WPT)-8\,W]PA@!=X6;YMHZX/1A[&F!ZK17/>#O$'_"2^'HKYT"3@
MF.95Z;AW'L1@T4@,'XN?\BO;?]?:_P#H+5G>&_B-H>D>'+#3[E+PS01!'V1
MC/MS7H>H:78ZK (+^UCN(@VX)(,@'UK._P"$+\-?] 6T_P"^* .:NOBYHT<1
M-M9WLTG8.JH/SR?Y5S.F:?JWQ$\41ZGJ$+1Z?$1DX(0(.=B9ZDGJ?<UZ?#X4
M\/V[!HM&L@PY!,(./SK65%C0*JA0.  , 4P%<8B8>QKRCX._\?VJ_P#7./\
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9HH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
